Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Riederer

Showing results (71-80 of 93) with videos related to

Pageof 10
Sort By:
Blood|July 13, 2000
Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factorU Rauch, D Bonderman, B Bohrmann, et al.
Thrombosis and Haemostasis|January 7, 2021
Insights from In Vitro and Clinical Data to Guide Transition from the Novel P2Y12 Antagonist Selatogrel to Clopidogrel, Prasugrel, and TicagrelorUta Schilling, Jasper Dingemanse, Michael Dobrow, et al.
Veterinary Journal (London, England : 1997)|January 18, 2017
Use of an implantable pump for controlled subcutaneous insulin delivery in healthy catsE Zini, I Padrutt, K Macha, et al.
Thrombosis Research|February 21, 2021
Selatogrel, a reversible P2Y12 receptor antagonist, has reduced off-target interference with haemostatic factors in a mouse thrombosis modelLydie Crescence, Roxane Darbousset, Eva Caroff, et al.
IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control|January 1, 1988
Measurement uncertainty assessment of the scanning laser acoustic microscope and application to canine skin and woundD L Steiger, W R O'Brien, J E Olerud, et al.
Bioorganic & Medicinal Chemistry Letters|January 18, 2013
Evolution of novel tricyclic CRTh2 receptor antagonists from a (E)-2-cyano-3-(1H-indol-3-yl)acrylamide scaffoldAnja Valdenaire, Julien Pothier, Dorte Renneberg, et al.
European Neurology|August 7, 1998
Histological markers in nasal mucosa of patients with Alzheimer's diseaseC Hock, S Golombowski, F Müller-Spahn, et al.
Journal of Medicinal Chemistry|June 1, 2013
Identification of 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid (setipiprant/ACT-129968), a potent, selective, and orally bioavailable chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonistHeinz Fretz, Anja Valdenaire, Julien Pothier, et al.
Biochemical Pharmacology|October 28, 2022
Inverse agonist efficacy of selatogrel blunts constitutive P2Y12 receptor signaling by inducing the inactive receptor conformationVéronique Pons, Cédric Garcia, Naomi Tidten-Luksch, et al.
Journal of Clinical Medicine|November 27, 2021
The P2Y12 Receptor Antagonist Selatogrel Dissolves Preformed Platelet Thrombi In VivoLydie Crescence, Markus Kramberg, Martine Baumann, et al.
Pageof 10

Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
Blood|July 13, 2000
Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factorU Rauch, D Bonderman, B Bohrmann, et al.
Thrombosis and Haemostasis|January 7, 2021
Insights from In Vitro and Clinical Data to Guide Transition from the Novel P2Y12 Antagonist Selatogrel to Clopidogrel, Prasugrel, and TicagrelorUta Schilling, Jasper Dingemanse, Michael Dobrow, et al.
Veterinary Journal (London, England : 1997)|January 18, 2017
Use of an implantable pump for controlled subcutaneous insulin delivery in healthy catsE Zini, I Padrutt, K Macha, et al.
Thrombosis Research|February 21, 2021
Selatogrel, a reversible P2Y12 receptor antagonist, has reduced off-target interference with haemostatic factors in a mouse thrombosis modelLydie Crescence, Roxane Darbousset, Eva Caroff, et al.
IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control|January 1, 1988
Measurement uncertainty assessment of the scanning laser acoustic microscope and application to canine skin and woundD L Steiger, W R O'Brien, J E Olerud, et al.
Bioorganic & Medicinal Chemistry Letters|January 18, 2013
Evolution of novel tricyclic CRTh2 receptor antagonists from a (E)-2-cyano-3-(1H-indol-3-yl)acrylamide scaffoldAnja Valdenaire, Julien Pothier, Dorte Renneberg, et al.
European Neurology|August 7, 1998
Histological markers in nasal mucosa of patients with Alzheimer's diseaseC Hock, S Golombowski, F Müller-Spahn, et al.
Journal of Medicinal Chemistry|June 1, 2013
Identification of 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid (setipiprant/ACT-129968), a potent, selective, and orally bioavailable chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonistHeinz Fretz, Anja Valdenaire, Julien Pothier, et al.
Biochemical Pharmacology|October 28, 2022
Inverse agonist efficacy of selatogrel blunts constitutive P2Y12 receptor signaling by inducing the inactive receptor conformationVéronique Pons, Cédric Garcia, Naomi Tidten-Luksch, et al.
Journal of Clinical Medicine|November 27, 2021
The P2Y12 Receptor Antagonist Selatogrel Dissolves Preformed Platelet Thrombi In VivoLydie Crescence, Markus Kramberg, Martine Baumann, et al.
Pageof 10